These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 21378390)
1. Melphalan as a treatment for BRCA-related ovarian carcinoma: can you teach an old drug new tricks? Osher DJ; Kushner YB; Arseneau J; Foulkes WD J Clin Pathol; 2011 Oct; 64(10):924-6. PubMed ID: 21378390 [TBL] [Abstract][Full Text] [Related]
2. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Wadler S; Yeap B; Vogl S; Carbone P Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766 [TBL] [Abstract][Full Text] [Related]
3. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
4. Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary. Dusenbery KE; Bellairs EE; Potish RA; Twiggs LB; Boente MP Gynecol Oncol; 2005 Feb; 96(2):307-13. PubMed ID: 15661213 [TBL] [Abstract][Full Text] [Related]
5. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S; J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344 [TBL] [Abstract][Full Text] [Related]
6. New options for the treatment of advanced ovarian cancer. Dunton CJ Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739 [TBL] [Abstract][Full Text] [Related]
7. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Thigpen T; Vance R; Puneky L; Khansur T Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816 [TBL] [Abstract][Full Text] [Related]
8. A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma. Weaver CH; Greco FA; Hainsworth JD; Zhen B; Baldwin P; Wittlin F; Lewis M; West WH; Schwartzberg L; Buckner CD Bone Marrow Transplant; 1997 Nov; 20(10):847-53. PubMed ID: 9404925 [TBL] [Abstract][Full Text] [Related]
9. Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin. Pater JL; Carmichael JA; Krepart GV; Fraser RC; Roy M; Kirk ME; Levitt M; Brown LB; Wilson KS; Shelley WE Cancer Treat Rep; 1987 Mar; 71(3):277-81. PubMed ID: 3102056 [TBL] [Abstract][Full Text] [Related]
10. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455 [TBL] [Abstract][Full Text] [Related]
11. Oral melphalan as a treatment for platinum-resistant ovarian cancer. Hasan J; Jayson GC Br J Cancer; 2003 Jun; 88(12):1828-30. PubMed ID: 12799622 [TBL] [Abstract][Full Text] [Related]
12. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370 [TBL] [Abstract][Full Text] [Related]
13. Improved survival in women with BRCA-associated ovarian carcinoma. Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470 [TBL] [Abstract][Full Text] [Related]
14. Melphalan for the treatment of patients with recurrent epithelial ovarian cancer. Davis-Perry S; Hernandez E; Houck KL; Shank R Am J Clin Oncol; 2003 Aug; 26(4):429-33. PubMed ID: 12902900 [TBL] [Abstract][Full Text] [Related]
15. [Combined chemo- and hormone-therapy in advanced ovarian carcinoma--theoretical, experimental foundations and clinical results]. Sevelda P Wien Klin Wochenschr Suppl; 1990; 183():3-29. PubMed ID: 2145702 [TBL] [Abstract][Full Text] [Related]
16. [Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma]. Gershanovich ML; Livshits ME; Antipenkova VI Vopr Onkol; 2000; 46(5):604-7. PubMed ID: 11202196 [TBL] [Abstract][Full Text] [Related]
17. Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging. Rubin SC; Wong GY; Curtin JP; Barakat RR; Hakes TB; Hoskins WJ Obstet Gynecol; 1993 Jul; 82(1):143-7. PubMed ID: 8515915 [TBL] [Abstract][Full Text] [Related]
18. Advances in the management of epithelial ovarian cancer. Berkenblit A; Cannistra SA J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567 [TBL] [Abstract][Full Text] [Related]
19. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results. Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406 [TBL] [Abstract][Full Text] [Related]
20. [First line chemotherapy for advanced ovarian cancer in 2000: standards and questions]. Cure H; Dauplat J; Cholet P Bull Cancer; 2000 Feb; 87(2):189-99. PubMed ID: 10705290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]